Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: GlobeNewswire
Multiple clinical data readouts across Ovid’s pipeline expected in 2020Completed financings in the fourth quarter strengthening the balance sheet NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of the Company’s recent progress and key clinical readouts anticipated in 2020. “We are entering a transformational period for Ovid,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. “2020 is a year where the team at Ovid looks to deliver on the hard work of the last several years. In anticipation of these important clinical readouts, during the fourth quarter of 2019 we raised approximately $56.0 million, providing us with sufficient capital to achieve all of thes
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at Citigroup Inc. from $4.00 to $3.50. They now have a "neutral" rating on the stock.MarketBeat
- Ovid Therapeutics Inc. (NASDAQ: OVID) is now covered by analysts at B. Riley. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
- Ovid Therapeutics Inc. (NASDAQ: OVID) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
- Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]Yahoo! Finance
- We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
OVID
Earnings
- 3/8/24 - Miss
OVID
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEF
- 4/24/24 - Form DEFA14A
- OVID's page on the SEC website